|
12
|
52
|
3q3kB |
Factor xa in complex with a phenylenediamine derivative |
|
62
|
233
|
3q3kA |
Factor xa in complex with a phenylenediamine derivative |
|
61
|
234
|
3m36A |
Factor xa in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-n-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (dpc423) |
|
12
|
52
|
3m36L |
Factor xa in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-n-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (dpc423) |
|
13
|
52
|
3m37L |
Factor xa in complex with the inhibitor 1-[2-(aminomethyl)phenyl]-n-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (dpc602) |
|
58
|
234
|
3m37A |
Factor xa in complex with the inhibitor 1-[2-(aminomethyl)phenyl]-n-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (dpc602) |
|
12
|
51
|
3liwB |
Factor xa in complex with (r)-2-(1-adamantylcarbamoylamino)-3-(3-carbamidoyl-phenyl)-n-phenethyl-propionic acid amide |
|
57
|
234
|
3liwA |
Factor xa in complex with (r)-2-(1-adamantylcarbamoylamino)-3-(3-carbamidoyl-phenyl)-n-phenethyl-propionic acid amide |
|
60
|
234
|
3kqcA |
Factor xa in complex with the inhibitor 6-(2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6- dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one |
|
13
|
52
|
3kqeL |
Factor xa in complex with the inhibitor 3-methyl-1-(3-(5- oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'- (pyrrolidin-1-ylmethyl)biphenyl-4-yl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin-7(4h)-one |
|
60
|
234
|
3kqbA |
Factor xa in complex with the inhibitor n-(3-fluoro-2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide |
|
12
|
50
|
3kl6B |
Discovery of tetrahydropyrimidin-2(1h)-one derivative tak-442: a potent, selective and orally active factor xa inhibitor |
|
12
|
52
|
3kqcL |
Factor xa in complex with the inhibitor 6-(2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6- dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one |
|
10
|
52
|
3kqdL |
Factor xa in complex with the inhibitor 1-(3-(5-oxo-4,5- dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'-(pyrrolidin-1- ylmethyl)biphenyl-4-yl)-3-(trifluoromethyl)-5,6-dihydro- 1h-pyrazolo[3,4-c]pyridin-7(4h)-one |
|
12
|
52
|
3kqbL |
Factor xa in complex with the inhibitor n-(3-fluoro-2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide |
|
61
|
238
|
3k9xB |
X-ray crystal structure of human fxa in complex with (s)-n-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2- (pyrrolidin-1-yl)ethyl)azepan-3- ylamino)methylene)nicotinamide |
|
60
|
234
|
3kqeA |
Factor xa in complex with the inhibitor 3-methyl-1-(3-(5- oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'- (pyrrolidin-1-ylmethyl)biphenyl-4-yl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin-7(4h)-one |
|
54
|
232
|
3kl6A |
Discovery of tetrahydropyrimidin-2(1h)-one derivative tak-442: a potent, selective and orally active factor xa inhibitor |
|
55
|
234
|
3kqdA |
Factor xa in complex with the inhibitor 1-(3-(5-oxo-4,5- dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'-(pyrrolidin-1- ylmethyl)biphenyl-4-yl)-3-(trifluoromethyl)-5,6-dihydro- 1h-pyrazolo[3,4-c]pyridin-7(4h)-one |
|
18
|
89
|
3k9xA |
X-ray crystal structure of human fxa in complex with (s)-n-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2- (pyrrolidin-1-yl)ethyl)azepan-3- ylamino)methylene)nicotinamide |
|
64
|
233
|
3iitA |
Factor xa in complex with a cis-1,2-diaminocyclohexane derivative |
|
12
|
54
|
3iitB |
Factor xa in complex with a cis-1,2-diaminocyclohexane derivative |
|
63
|
238
|
3hptB |
Crystal structure of human fxa in complex with (s)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine |
|
17
|
89
|
3hptA |
Crystal structure of human fxa in complex with (s)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine |
|
58
|
234
|
3ffgA |
Factor xa in complex with the inhibitor (r)-6-(2'-((3- hydroxypyrrolidin-1-yl)methyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1h-pyrazolo[3,4-c]pyridin- 7(4h)-one |
|
13
|
52
|
3ffgL |
Factor xa in complex with the inhibitor (r)-6-(2'-((3- hydroxypyrrolidin-1-yl)methyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1h-pyrazolo[3,4-c]pyridin- 7(4h)-one |
|
64
|
238
|
3ensB |
Crystal structure of human fxa in complex with methyl (2z)-3-[(3-chloro-1h-indol-7-yl)amino]-2-cyano-3-{[(3s)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]amino}acrylate |
|
19
|
89
|
3ensA |
Crystal structure of human fxa in complex with methyl (2z)-3-[(3-chloro-1h-indol-7-yl)amino]-2-cyano-3-{[(3s)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]amino}acrylate |
|
13
|
52
|
3cs7L |
Factor xa in complex with the inhibitor 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one |
|
60
|
234
|
3cs7A |
Factor xa in complex with the inhibitor 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one |
|
63
|
234
|
3cenA |
Factor xa in complex with the inhibitor n-(2-(((5-chloro-2-pyridinyl) amino)sulfonyl)phenyl)-4-(2-oxo-1(2h)-pyridinyl)benzamide |
|
13
|
52
|
3cenL |
Factor xa in complex with the inhibitor n-(2-(((5-chloro-2-pyridinyl) amino)sulfonyl)phenyl)-4-(2-oxo-1(2h)-pyridinyl)benzamide |
|
12
|
54
|
2y5fL |
Factor xa - cation inhibitor complex |
|
65
|
234
|
2y80A |
Structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs |
|
61
|
234
|
2y7xA |
The discovery of potent and long-acting oral factor xa inhibitors with tetrahydroisoquinoline and benzazepine p4 motifs |
|
12
|
52
|
2y7xB |
The discovery of potent and long-acting oral factor xa inhibitors with tetrahydroisoquinoline and benzazepine p4 motifs |
|
62
|
233
|
2y5fA |
Factor xa - cation inhibitor complex |
|
63
|
234
|
2y7zA |
Structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs |
|
13
|
52
|
2y82B |
Structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs |
|
12
|
54
|
2y5gL |
Factor xa - cation inhibitor complex |
|
62
|
234
|
2y82A |
Structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs |
|
12
|
52
|
2y81B |
Structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs |
|
12
|
52
|
2y80B |
Structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs |
|
64
|
233
|
2y5hA |
Factor xa - cation inhibitor complex |
|
62
|
233
|
2y81A |
Structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs |
|
12
|
54
|
2y5hL |
Factor xa - cation inhibitor complex |
|
12
|
52
|
2y7zB |
Structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs |
|
63
|
233
|
2y5gA |
Factor xa - cation inhibitor complex |
|
61
|
234
|
2xbyA |
Factor xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor |
|
9
|
50
|
2xc0L |
Factor xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor |
